Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965097 | PMC |
| http://dx.doi.org/10.1093/rheumatology/key116 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
What Is New in Morphea-Narrative Review on Molecular Aspects and New Targeted Therapies.
J Clin Med
November 2024
Department of Dermatology, Poznan University of Medical Sciences, 60-806 Poznan, Poland.
Article Synopsis
- Morphea, or localized scleroderma, is an autoimmune disease marked by excessive collagen buildup in the skin, with unclear causes that may include genetic, environmental, and epigenetic factors.
- Advances in medicine suggest genetic and epigenetic influences may significantly impact the disease's risk and progression, highlighting the role of factors like microRNAs and DNA methylation.
- New treatment options, including biological therapies and JAK inhibitors, show promise based on case studies, underscoring the need for further exploration of morphea's pathogenesis and treatment strategies.
Cost-effectiveness analysis of subcutaneous biosimilar tocilizumab in patients with rheumatoid arthritis in Spain.
Farm Hosp
December 2024
Hospital Universitario Doctor Peset, Valencia, Spain. Electronic address:
Introduction: Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease, its management and morbidity impose a great burden to healthcare systems. Development and rollout of biological disease modifying anti-rheumatic drugs has contributed to improvements for patients, however, high costs have prevented them to be widely used. This is being addressed with biosimilars, with equal benefit-risk profile and reduced costs.
View Article and Find Full Text PDFA case of polyarteritis nodosa with severe lower limb ulcer that was treated with prednisolone and tocilizumab.
Mod Rheumatol Case Rep
December 2024
Nephrology Center and Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Polyarteritis nodosa (PAN) is a rare systemic necrotizing vasculitis that can lead to the formation of refractory lower limb ulcers requiring amputation. The standard treatment for severe PAN involves combination therapy with steroids and cyclophosphamide; however, some cases prove to be challenging. Recently, case reports have described the use of biological agents for PAN treatment.
View Article and Find Full Text PDFTocilizumab for Advanced Non-Small-Cell Lung Cancer With Concomitant Cachexia: An Observational Study.
J Cachexia Sarcopenia Muscle
December 2024
Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Background: Cancer cachexia significantly contributes to morbidity and mortality in patients with non-small-cell lung cancer (NSCLC). Inflammatory pathways mediated by interleukin-6 (IL-6) play a crucial role in the development of cancer cachexia. This study aimed to investigate the use of tocilizumab in the management of NSCLC with coexisting IL-6-elevated cachexia.
View Article and Find Full Text PDFUse of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).
Rev Med Interne
January 2025
Service de Médecine Interne et Immunologie Clinique, CHU de Dijon, Dijon, France.
Article Synopsis
- The purpose of this project was to update the 2016 recommendations regarding the management of immunosuppressants or biologics in patients with giant cell arteritis (GCA).
- A task force of 18 physicians developed 26 validated recommendations after thorough discussion and a >85% consensus process.
- Key recommendations include using subcutaneous tocilizumab (TCZ) as a first-line treatment when glucocorticoid-sparing is needed, initiating TCZ at diagnosis for patients with specific high-risk conditions, and considering TCZ or methotrexate if glucocorticoid discontinuation is not feasible after 12 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!